期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 13, 期 6, 页码 719-728出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2015.0087
关键词
-
类别
资金
- Eisai
- Bristol-Myers Squibb
- Genentech BioOncology
- Merck
- Novartis Oncology
- Novocure
- Boehringer Ingelheim Pharmaceuticals, Inc.
The NCCN Guidelines for Rectal Cancer begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease, and survivorship. The NCCN Rectal Cancer Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize major discussion points from the 2015 NCCN Rectal Cancer Panel meeting. Major discussion topics this year were perioperative therapy options and surveillance for patients with stage I through III disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据